Skip to content
Back to news
IndustryNovember 16, 2026

Cellectis to Cut Up to 70% of Staff After Dropping Its CAR-T Trials

Cellectis to Cut Up to 70% of Staff After Dropping Its CAR-T Trials: PharmoniQ news card

Cellectis plans to cut up to 70% of its staff as it winds down its own CAR-T cell therapy trials and moves to in vivo gene editing. The company disclosed the plan in its third quarter results, dated Nov. 12. It has sites in Paris, New York and Raleigh, North Carolina.

What happened

Cellectis said it expects to reduce headcount by up to 70% from its level before the shift, with the cuts spread over 2026 and 2027. The plan still depends on consultation with its French works council and on French and US labour law.

The company had 229 full-time employees at Dec. 31, 2025, according to BioSpace. BioSpace worked out that the reduction could affect as many as 160 people. A spokesperson did not give a breakdown by site.

Cellectis has stopped enrolling patients in its studies of lasme-cel and eti-cel, two donor-derived CAR-T candidates. It is closing out the trial sites and wants to find partners to take both programs forward.

The company reported cash, cash equivalents and fixed-term deposits of $149 million as of Sept. 30, 2026. It expects that money to fund operations into the second half of 2028.

Why it matters

The shift ends Cellectis's own work on CAR-T therapy made from donor cells. Its board approved the move on Sept. 11, 2026. When the change was announced three days later, BioPharma Dive reported that the shares fell as much as 43% in morning trading.

The new focus is gene editing done inside the body for chronic metabolic disease. HEAL-101 targets the APOC3 gene in severe hypertriglyceridemia. HEAL-201 targets PCSK9 in severe hypercholesterolemia. Cellectis puts the target population for each program at about 1 to 2 million patients in the US and Europe.

Both programs are early. BioSpace reported that Cellectis plans investigator-led studies in China, with data expected in the second half of 2027 and the first half of 2028.

Partnered cell therapy work goes on. Cellectis said its research deal with AstraZeneca, covering up to 10 products, continues. Allogene is still running a trial of cema-cel, and Iovance is enrolling patients for IOV-4001.

What it means for people in the industry

The cuts are spread over 2026 and 2027, and Cellectis has not said how they split between France and the US. Asked for more detail, a spokesperson pointed to the French works council process and French and US labour law.

Cellectis says its people and money will now go mainly to the two gene editing candidates. It will also keep backing its existing cell therapy partners.

See open pharma jobs in the US and Canada

Sources

Check Your Supplement Interactions

Use our AI-powered checker to analyze supplement safety and interactions.

Open Interaction Checker →

Comments (0)

Leave a comment

Your email is not shown. Please keep it civil and do not give medical advice. Comment rules

This article is for informational purposes only and does not constitute medical or investment advice. It was written with AI assistance from the sources listed above. Check the original sources before relying on any detail.